MHYOSPHERE®PCV ID: ESPHM Publications 2021

MHYOSPHERE® PCV ID is the first and only vaccine based on a recombinant Mycoplasma hyopneumoniae (M. hyo) strain, called Nexyhon. This strain expresses the capsid proteins of Porcine Circovirus Type 2 (PCV2) in its cytoplasm and acts as the only active substance as a whole once inactivated. Furthermore, it was the first vaccine registered in Europe with demonstrated protection against all three PCV2 genotypes (a, b and d).
calendar icon 13 July 2021
clock icon 9 minute read
Figure 1. Percentage of lung surface area affected by M. hyo-like lesions.  *Different letters indicate statistically significant differences, p <0.05,  Welch’s test.
Figure 1. Percentage of lung surface area affected by M. hyo-like lesions. *Different letters indicate statistically significant differences, p <0.05, Welch’s test.
Figure 2. Viraemia due to PCV2 (qPCR). The area under the curve (AUC)  was lower in the vaccinated group (p <0.05, Mann–Whitney U test).
Figure 2. Viraemia due to PCV2 (qPCR). The area under the curve (AUC) was lower in the vaccinated group (p <0.05, Mann–Whitney U test).
Figure 3. Percentage of lung surface area affected by lesions consistent  with M. hyo. Different letters indicate statistically significant differences, p  <0.0001, Mann–Whitney U test.
Figure 3. Percentage of lung surface area affected by lesions consistent with M. hyo. Different letters indicate statistically significant differences, p <0.0001, Mann–Whitney U test.
Figure 4. Viraemia due to PCV2. The area under the curve (AUC) was lower in the vaccinated group (p <0.001, mixed linear model).
Figure 4. Viraemia due to PCV2. The area under the curve (AUC) was lower in the vaccinated group (p <0.001, mixed linear model).
Table 1. Area under the curve (AUC) of the group vaccinated with  MHYOSPHERE® PCV ID, and the control group, grouped by PCV2 genotype.  Different superscripts indicate statistically significant differences.
Table 1. Area under the curve (AUC) of the group vaccinated with MHYOSPHERE® PCV ID, and the control group, grouped by PCV2 genotype. Different superscripts indicate statistically significant differences.
Table 2. ADG ± standard error of measurement (SEM) during different  production periods. Units expressed in grams per day.
Table 2. ADG ± standard error of measurement (SEM) during different production periods. Units expressed in grams per day.
Figure 5. Mean body weight (± SEM) at the end of fattening
Figure 5. Mean body weight (± SEM) at the end of fattening
References
References
1. Montané, J.; Simon-Grifé, M.; Moros, A.; Puigvert, E.; González-González, L.; Pedernera, C.; Acal, L.; Sitjà, M.: Duration of immunity of a novel intradermal vaccine against Mycoplasma hyopneumoniae and PCV2 infection, ESPHM 2021, IMM-PP-25.
2. Montané, J.; Simon-Grifé, M.; Moros, A.; Puigvert, E.; González-González, L.; Pedernera, C.; Acal, L.; Sitjà, M.: Efficacy of a new intradermal vaccine against Mycoplasmahyopneumoniae and PCV2 infection. ESPHM 2021, IMMPP-29
3. Puig, A.; Perozo, E.; Sabaté, D.; Moros, A.; Roura, F.; March, R.; Montané, J.; Effect of Mhyosphere® PCV ID on the gowth performance under field conditions, ESPHM 2021, IMM-PP-20.

Nacho Bernal

Hipra

Ramon Jordà

Hipra
© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.